Inside the study for a remedy to fight Congo’s deadliest Ebola outbreak

RWAMPARA, Congo (AP) — Over 250 individuals have joined a trial for a potential Ebola medication in Congo, considered a crucial step in combating the country's deadliest outbreak. The drug targets the Bundibugyo virus, responsible for the rapid spread of the current disease outbreak and lacking an approved vaccine or treatment. The trial commenced in July and is among several studies initiated to provide protection and a means to slow the outbreak.

The Associated Press interviewed participants and doctors at the health center in eastern Ituri province, the outbreak's epicenter. Participants comprise individuals exposed to the disease, including healthcare workers and relatives of patients. Recorded cases total 8,300, with 4,000 deaths.

The trial evaluates Gilead’s experimental antiviral pill, obeldesivir, administered shortly after suspected contact with the virus to prevent disease development, known as post-exposure prophylaxis (PEP). The drug aims to stop the disease before it spreads.

One trial participant, who requested anonymity, enrolled after her husband tested positive for Ebola. So far, no one from her family exhibited symptoms. Participants emphasized the urgency of precautionary measures due to the disease's rapid progression once symptoms emerge.

ALIMA, a medical nonprofit, coordinates the trial, aiming to recruit nearly 1,000 adults or children over 12 who have had contact with a confirmed case within five days but show no symptoms. Half receive a placebo. Participants are monitored daily for 21 days, with a final phone call after 42 days, according to Dr. Godefroid Basara.

If the pill proves effective, it could help break the infection chain. Unlike a vaccine, which may take days or weeks to provide protection, the pill is intended for people showing no symptoms. Dr. Guilavogui Jean Paul Yassa, ALIMA's research coordinator, noted the challenge of encouraging participation from those living far from the center, especially when family members have died from the disease.